In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
|Articles|December 21, 2017
AAHRPP Accredits Four More Research Organizations
Advertisement
WASHINGTON, D.C.âThe Association for the Accreditation of Human Research Protection Programs today announced that it has accredited four more research organizations-one each in the U.S., Canada, Korea, and Taiwan.
The newly accredited organizations are:
- BC Diabetes, Vancouver, British Columbia, Canada
- Boston Medical Center and Boston University Medical Campus, Boston, Massachusetts
- Chang Gung Medical Foundation, Taipei City, Taiwan
- Korea University Medical Center, Seoul, Korea
They join 18 other organizations in earning AAHRPP accreditation this year, bringing the total to 22 in 2017 and 251 accredited organizations overall. Of those, 49 are outside the U.S.
“This was a good year for AAHRPP accreditation and for the research participants that AAHRPP’s high standards help protect,” AAHRPP President and CEO Elyse I. Summers said.
“AAHRPP accreditation has long been recognized as the gold standard for research protections and as evidence of an organization’s commitment to high-quality, ethical research,” she added. “In an increasingly collaborative research enterprise, accreditation is more valuable than ever because it signals that an organization is a trusted partner.”
To earn accreditation, organizations must show that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research.
AAHRPP has accredited organizations across the United States and in Belgium, Brazil, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, South Africa, Taiwan and Thailand.
All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, 70 percent of U.S. medical colleges and 84 percent of the top National Institute of Health-funded academic medical centers are either AAHRPP accredited or have begun the accreditation process. NIH, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
About AAHRPP:
A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit
###
FOR MORE INFORMATION CONTACT:
Sarah Kiskaddon
Vice President, Global Development and Public Affairs
skiskaddon@aahrpp.org
(202) 783-1112
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Where AI Governance in Clinical Development Falls Short
5